JP2002503676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002503676A5 JP2002503676A5 JP2000531476A JP2000531476A JP2002503676A5 JP 2002503676 A5 JP2002503676 A5 JP 2002503676A5 JP 2000531476 A JP2000531476 A JP 2000531476A JP 2000531476 A JP2000531476 A JP 2000531476A JP 2002503676 A5 JP2002503676 A5 JP 2002503676A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- disease
- macrophage
- antibody
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002540 macrophage Anatomy 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000009109 Fc receptors Human genes 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WMTIOGUVKBSEOW-UHFFFAOYSA-N ClC1(Cl)OP(=O)OP(=O)O1 Chemical compound ClC1(Cl)OP(=O)OP(=O)O1 WMTIOGUVKBSEOW-UHFFFAOYSA-N 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7496798P | 1998-02-17 | 1998-02-17 | |
| US60/074,967 | 1998-02-17 | ||
| PCT/US1999/003488 WO1999041285A1 (en) | 1998-02-17 | 1999-02-17 | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002503676A JP2002503676A (ja) | 2002-02-05 |
| JP2002503676A5 true JP2002503676A5 (https=) | 2006-03-30 |
Family
ID=22122724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531476A Pending JP2002503676A (ja) | 1998-02-17 | 1999-02-17 | Ｆｃレセプターのリガンドを使用するマクロファージ媒介性疾患の治療および診断 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20020058284A1 (https=) |
| EP (1) | EP1056781A1 (https=) |
| JP (1) | JP2002503676A (https=) |
| KR (1) | KR20010041010A (https=) |
| CN (1) | CN1307590A (https=) |
| AU (1) | AU2772199A (https=) |
| CA (1) | CA2321136A1 (https=) |
| EA (1) | EA200000848A1 (https=) |
| HK (1) | HK1038931A1 (https=) |
| HU (1) | HUP0100929A3 (https=) |
| IL (1) | IL137919A0 (https=) |
| NO (1) | NO20004098L (https=) |
| PL (1) | PL342729A1 (https=) |
| SI (1) | SI20475A (https=) |
| WO (1) | WO1999041285A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756396B1 (en) * | 1997-05-07 | 2004-06-29 | Qlt Inc. | Ethylene glycol esters as photoactive agents |
| CN101979095A (zh) | 2001-05-02 | 2011-02-23 | 普渡研究基金会 | 巨噬细胞介导的疾病的治疗和诊断 |
| US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
| DK1534335T4 (en) * | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US20100297074A1 (en) * | 2002-12-23 | 2010-11-25 | Richard Hans Gomer | Wound healing compositions, systems, and methods |
| US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US8012472B2 (en) * | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| WO2007094776A1 (en) * | 2006-02-15 | 2007-08-23 | William Marsh Rice University | Compositions and methods for suppressing fibrocyte differentiation |
| PT1596880E (pt) | 2002-12-23 | 2011-06-06 | Univ Rice William M | Métodos e composições para suprimir a diferenciação de fibrócitos |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20060204565A1 (en) * | 2003-05-06 | 2006-09-14 | Low Philip S | Conjugates and use thereof |
| US20050008633A1 (en) * | 2003-05-19 | 2005-01-13 | Advanced Inhalation Research Inc. | Chemical and physical modulators of bioavailability of inhaled compositions |
| BG65715B1 (bg) * | 2003-09-04 | 2009-08-31 | Чавдар ВАСИЛЕВ | Средство за селективно подтискане на патологични днк - специфични в клетки |
| US7057624B2 (en) * | 2003-10-28 | 2006-06-06 | Eastman Kodak Company | Display device light leakage compensation |
| EP1570858A1 (en) | 2004-03-05 | 2005-09-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| WO2006060664A2 (en) * | 2004-12-03 | 2006-06-08 | The Uab Research Foundation | Single-drug multi-ligand conjugates for targeted drug delivery |
| US20060128031A1 (en) * | 2004-12-15 | 2006-06-15 | Robotti Karla M | Addressable recovery of bound analytes from an evanescent wave sensor |
| EP1904183B1 (en) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmaceutical composition for the treatment of osteoarthritis |
| US8795633B2 (en) | 2005-09-23 | 2014-08-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
| WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| ES2599319T3 (es) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Anticuerpos específicos de Fc RIIB y métodos de uso de éstos |
| JP2010509570A (ja) | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
| ES2409756T3 (es) | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| US8586595B2 (en) | 2007-02-07 | 2013-11-19 | Purdue Research Foundation | Positron emission tomography imaging method |
| WO2008148001A2 (en) | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| ES2589912T3 (es) | 2008-04-02 | 2016-11-17 | Macrogenics, Inc. | Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos |
| WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
| CA2754961C (en) * | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
| EP2405929B1 (en) * | 2009-03-11 | 2018-06-06 | Promedior Inc. | A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| EP2987803B1 (en) | 2009-06-17 | 2018-08-29 | Promedior Inc. | Sap variants and their use |
| CA2770771C (en) | 2009-08-10 | 2019-12-03 | Fundacao Oswaldo Cruz | Monoclonal antibodies for pbp2-a protein and homologous sequences for treatment of infections and immunodiagnosis on bacteria from phylum firmicutes |
| JP5898082B2 (ja) | 2009-10-07 | 2016-04-06 | マクロジェニクス，インコーポレーテッド | フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| KR102006997B1 (ko) * | 2012-07-03 | 2019-08-02 | 한국생명공학연구원 | ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| GEP20227398B (en) | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
| CN109490540A (zh) * | 2017-09-13 | 2019-03-19 | 中国科学院上海药物研究所 | 单核/巨噬细胞在主动脉损伤中的诊断和治疗应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4470925A (en) * | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US5635600A (en) * | 1986-07-07 | 1997-06-03 | Trustees Of Dartmouth College | Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes |
| US4869903A (en) * | 1987-05-29 | 1989-09-26 | Genelabs Incorporated | Method of selectively inhibiting HIV |
| US5026557A (en) * | 1987-09-09 | 1991-06-25 | The Liposome Company, Inc. | Adjuvant composition |
| US5840840A (en) * | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
| US5767106A (en) * | 1992-02-21 | 1998-06-16 | Hyal Pharmaceutical Corporation | Treatment of disease and conditions associated with macrophage infiltration |
| US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
| GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| IL111105A (en) * | 1993-09-30 | 2009-05-04 | Univ Pennsylvania | Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis |
| US5578706A (en) * | 1993-11-04 | 1996-11-26 | Board Of Regents, The University Of Texas | Methods and compositions concerning homogenous immunotoxin preparations |
| US5580715A (en) * | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| EP0929300B1 (en) * | 1996-09-06 | 2004-05-26 | Medarex, Inc. | Cyanidin compositions and therapeutic and diagnostic uses therefor |
-
1999
- 1999-02-17 KR KR1020007009038A patent/KR20010041010A/ko not_active Ceased
- 1999-02-17 JP JP2000531476A patent/JP2002503676A/ja active Pending
- 1999-02-17 CA CA002321136A patent/CA2321136A1/en not_active Abandoned
- 1999-02-17 CN CN99805129A patent/CN1307590A/zh active Pending
- 1999-02-17 IL IL13791999A patent/IL137919A0/xx unknown
- 1999-02-17 HK HK02100608.2A patent/HK1038931A1/zh unknown
- 1999-02-17 US US09/251,570 patent/US20020058284A1/en not_active Abandoned
- 1999-02-17 WO PCT/US1999/003488 patent/WO1999041285A1/en not_active Ceased
- 1999-02-17 HU HU0100929A patent/HUP0100929A3/hu unknown
- 1999-02-17 SI SI9920025A patent/SI20475A/sl not_active IP Right Cessation
- 1999-02-17 EP EP99908236A patent/EP1056781A1/en not_active Ceased
- 1999-02-17 EA EA200000848A patent/EA200000848A1/ru unknown
- 1999-02-17 AU AU27721/99A patent/AU2772199A/en not_active Abandoned
- 1999-02-17 PL PL99342729A patent/PL342729A1/xx not_active Application Discontinuation
-
2000
- 2000-08-16 NO NO20004098A patent/NO20004098L/no not_active Application Discontinuation
-
2003
- 2003-07-25 US US10/627,307 patent/US20040141967A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002503676A5 (https=) | ||
| Portoles et al. | Monoclonal antibodies to murine CD3 epsilon define distinct epitopes, one of which may interact with CD4 during T cell activation. | |
| KR20210018336A (ko) | 항인터류킨-17a 항체, 그의 약학 조성물 및 용도 | |
| US20040210040A1 (en) | Amphiregulin antibodies and their use to treat cancer and psoriasis | |
| KR20080031049A (ko) | 항-ανβ6 항체 및 이의 용도 | |
| JP2017035086A (ja) | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 | |
| KR20180048712A (ko) | Tl1a에 특이적으로 결합하는 항체 | |
| BG63549B1 (bg) | Рекомбинантни интерлевкин-4-антитела, използвани за лечение на интерлевкин-4- медиирани неразположения | |
| CA2351887A1 (en) | Psca: prostate stem cell antigen and uses thereof | |
| KR20170036503A (ko) | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 | |
| CN101903044A (zh) | 对人铁调素具有特异性的抗原结合蛋白 | |
| CA3159465A1 (en) | Humanized cldn18.2 antibodies | |
| JPWO1997002290A1 (ja) | 抗Ｆａｓリガンド抗体および該抗体を用いた測定法 | |
| US20230088269A1 (en) | Anti-il-22r antibodies | |
| JP2019524052A (ja) | ＦｃγＲＩＩＡに特異的な結合分子及びその使用 | |
| US20030166196A1 (en) | Fusion proteins and polynucleotides encoding gelonin sequences | |
| CA3162773A1 (en) | Tumor-specific claudin 18.2 antibodies | |
| US20050142137A1 (en) | Antibodies against secretoryleukocyte protease inhibitor | |
| CN120712286A (zh) | 抗体、抗原结合片段和使用方法 | |
| Poul et al. | Cassette baculovirus vectors for the production of chimeric, humanized, or human antibodies in insect cells | |
| Hamilton et al. | Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies | |
| JP6940732B2 (ja) | がん細胞特異的抗ポドカリキシン抗体とその製造方法 | |
| CN117715942A (zh) | 使用抗体-寡核苷酸缀合物的增强的靶向 | |
| KR20110075052A (ko) | 가용형 ｌｏｘ―１에 대한 단일 클론 항체 | |
| JP6887613B2 (ja) | がん微小環境を標的とした抗ポドカリキシン抗体 |